Navigation Links
Antibody responses in patients with Lyme arthritis
Date:11/28/2007

Lyme disease in the U.S. is caused by a form of bacteria, the spirochete Borrelia burgdorferi, infecting humans by tick bites. It typically begins with a bulls-eye skin rash, accompanied by fever, muscle aches, or other flu-like symptoms. If diagnosed early, Lyme can be treated successfully within a month with either oral or intravenous antibiotics. Nearly 60 percent of patients who do not receive antibiotic therapy early in the illness develop intermittent or persistent arthritis, particularly affecting the knees. Moreover, a small percentage of Lyme patients who do receive antibiotic therapy suffer from persistent arthritis for months or even several years after 2-3 months of oral and intravenous antibiotic therapy. This confounding condition has been termed antibiotic-refractory, or slowly resolving, Lyme arthritis.

To gain insights into the survival of spirochetes following antibiotic therapy, researchers at the Center for Immunology and Inflammatory Diseases at Massachusetts General Hospital, Harvard Medical School, and the National Center for Infectious Diseases at the Centers for Disease Control and Prevention teamed up to study antibody responses to Borrelia burgdorferi in patients with antibiotic-refractory or antibiotic-responsive Lyme arthritis. Presented in the December 2007 issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/journal/arthritis), their findings indicate that joint inflammation persists in patients with antibiotic-refractory Lyme arthritis after the disease-spreading spirochetes have been killed.

To compare antibody responses and determine their effect on Lyme arthritis, the team tested at least 3 blood serum samples each from 41 patients with antibiotic-refractory arthritis, 23 patients with antibiotic-responsive arthritis, and 10 non-antibiotic-treated controls arthritis patients who had contracted Lyme disease during the late 1970s before the cause of the disease was known. Samples were obtained during the period of arthritis and sometimes after several months of remission for all patient groups. The patients with antibiotic-refractory and antibiotic-responsive arthritis had a similar age range, sex distribution, and duration of arthritis prior to antibiotic therapy.

All samples were tested for IgG reactivity with Borrelia burgdorferi bacteria and 4 outer surface lipoproteins of the spirochete. Among non-antibiotic-treated patients, antibody titers to Borrelia burgdorferi remained high throughout a prolonged period of persistent arthritis, 2 to 5 years. In contrast, in patients with antibiotic-responsive arthritis, the level of antibody titers to Borrelia burgdorferi and most outer-surface proteins remained steady or decreased within the first 3 months of starting antibiotic therapy. Consistent with this finding, these patients usually experienced relief from joint swelling during a 1-month course of oral antibiotics. In patients afflicted with antibiotic-refractory arthritis, the level of antibody titers to Borrelia burgdorferi and most outer-surface antigens increased slightly during the first 1 to 3 months of treatment. These patients suffered from persistent joint swelling for a median duration of 10 months, despite 2 to 3 months of oral or intravenous antibiotics. However, by 4 to 6 months after starting antibiotic therapy, antibody titers declined to similar levels in both antibiotic-treated groups, regardless of their differences in arthritis symptoms.

In Lyme disease, there is a great need for a test that could be used in clinical practice as a marker for spirochetal eradication, observes Dr. Allen C. Steere, the senior author of the study. Yet, as he acknowledges, ridding the body of the Borrelia burgdorferi bacteria and its surface antigens does not always bring relief from arthritis. Increasing antibody titers in patients usually suggested the presence of live spirochetes, whereas declining titers suggested that they had been killed, he notes. Thus, patients with Lyme arthritis who have a sustained, gradual decline in antibody reactivity probably have the nearly complete or total eradication of spirochetes from the joint as a result of antibiotic therapy, even if joint inflammation persists after the period of infection.


'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
2. Antibody leads to repair of myelin sheath in lab study of multiple sclerosis and related disorders
3. Antibody Helps Repair MS Nerve Damage
4. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
5. ThromboGenics Begins Preclinical Development of Anti-VPAC Antibody for Thrombocytopenia
6. NIAID funds $51M contract to create comprehensive model of immune responses
7. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
8. Comparison of obstetric outcomes between on-call and patients own obstetricians
9. Vision restoration therapy shown to improve brain activity in brain injured patients
10. Diabetes appears to increase risk of death for patients with acute coronary syndromes
11. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... ... Silverado today is pleased to announce that it has entered into a management ... Alexandria, Virginia. The new community is expected to open its doors in the first ... three-story community with underground parking – located on King Street –will serve 66 people ...
(Date:2/20/2017)... Orlando, FL (PRWEB) , ... February 20, 2017 ... ... Director, beth[at]orbitahealth[dot]com, +1 (414) 213-8818 , Orbita, Inc., a leading provider of innovative ... software-as-a-service solution for increasing patient engagement and optimizing care journey management for home ...
(Date:2/20/2017)... ... , ... Clearwave is the leading provider in ... XT-series of touch screen terminals. Both companies will be showcasing their solutions at ... provider Posiflex is helping to bridge the gap between healthcare hardware and software ...
(Date:2/20/2017)... , ... February 20, 2017 , ... ... regulated industries, announced Biscom Document Router (BDR), the first IoT device from Biscom ... diagnostics and imaging. Biscom will debut BDR at HIMSS17 and will ...
(Date:2/20/2017)... ... 2017 , ... Best Doctors® and IBM today announced that ... that want to help members of their workforce battling cancer. Through the Best ... suite of oncology offerings for insights on cancer treatment options, ranging from standard ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... , Feb. 21, 2017 Research and Markets ... Devices - Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive ... , Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. Also, a ...
(Date:2/21/2017)... Research and Markets has announced the addition of the ... their offering. ... research Uterine cancer Drugs Price Analysis and Strategies - 2016, provides drug ... The research answers the following questions: What are ... are they positioned in the Global Uterine cancer market? ...
(Date:2/20/2017)... Feb. 20, 2017   MedPlast, Inc. , ... industry, announced today that it has signed a ... Device Manufacturing Services business.   The acquisition broadens MedPlast,s ... a leading services provider to the world,s largest ... further expand the company,s capabilities in assembly and ...
Breaking Medicine Technology: